This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Journal of Clinical Investigation
jci.org
did:plc:dp6fotbhabsloue6hd2bec2s
A rationale for combining KRAS/ERK inhibitors with standard-of-care chemotherapies in pancreatic cancer
David M. Virshup & team report on the suppression of the master regulator of differentiation and chemosensitivity—GATA6 expression—in PC models: https://doi.org/10.1172/JCI191370
2026-02-02T17:15:15.461Z